Bitcoin price today: dips below $112k, near 6-wk low despite Fed cut bets
In a recent transaction, Greg Keenan, the Chief Medical (TASE:BLWV) Officer of Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH), a $1.12 billion market cap company with strong financial health indicators, sold 8,305 shares of common stock. The shares were sold at a weighted average price of $8.23, resulting in a total transaction value of $68,350. According to InvestingPro data, the company maintains robust liquidity with a current ratio of 4.57.
The sale, which took place on March 7, 2025, was conducted to cover tax withholding obligations related to the vesting of Restricted Stock Units from a March 6, 2023 grant. Following this transaction, Keenan holds 153,484 shares directly. The stock has shown strong momentum, delivering a 50% return over the past year, and InvestingPro analysis suggests the stock is currently undervalued. Discover 10+ additional exclusive ProTips and comprehensive financial metrics with an InvestingPro subscription.
The shares were sold in multiple transactions at prices ranging from $8.20 to $8.25. Keenan has committed to providing detailed information on the number of shares sold at each price upon request. The company has demonstrated strong revenue growth of 34% over the last twelve months, while management has been actively buying back shares.
In other recent news, Aurinia Pharmaceuticals reported its fourth-quarter 2024 earnings, revealing an earnings per share (EPS) of $0.01, which fell short of analysts’ expectations of $0.03. The company’s revenue also missed forecasts, reaching $59.9 million against a projected $61.7 million. Despite the shortfall in expectations, Aurinia Pharmaceuticals demonstrated significant revenue growth for the full year, with total revenue increasing by 34% year-over-year to $235.1 million. The company’s flagship product, LUKINIS, reported net product sales of $216.2 million for the year, marking a 36% increase from 2023. Looking ahead to 2025, Aurinia Pharmaceuticals has set a total revenue guidance of $250 million to $260 million, with net product sales expected to range from $240 million to $250 million. The company is also advancing its pipeline, particularly with AUR200, and is preparing for potential generic competition. CEO Peter Greenleaf emphasized the company’s commitment to defending its intellectual property rights for LUKINIS. Additionally, Aurinia Pharmaceuticals continues to focus on expanding its market presence and product offerings.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.